The oncological outcomes are encouraging, with a 95% reduction in PSA levels at 12 mo, 89% of patients showing no cancer on biopsy in the targeted area, and 78% being cancer free on biopsy across the entire prostate. The gene discussed is KLK3; the disease is cancer.